Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights
Introduction: Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clin...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2025-07-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://dpcj.org/index.php/dpc/article/view/5921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388660839940096 |
|---|---|
| author | Marco Ardigò Giuseppe Argenziano Elena Campione Stefania Guida Caterina Longo Giuseppe Micali Gianluca Nazzaro Ketty Peris Federico Venturi Alessia Villani Iris Zalaudek |
| author_facet | Marco Ardigò Giuseppe Argenziano Elena Campione Stefania Guida Caterina Longo Giuseppe Micali Gianluca Nazzaro Ketty Peris Federico Venturi Alessia Villani Iris Zalaudek |
| author_sort | Marco Ardigò |
| collection | DOAJ |
| description |
Introduction: Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful.
Objectives: The aim of this article is to deliver advice, via expert consensus, on optimal use of tirbanibulin in the real-life management of AK.
Methods: A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients, based on selected literature data and their own clinical experience.
Results: Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements were elaborated and voted, concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities and key messages for patient communication.
Conclusion: Tirbanibulin should be considered as a first-line option for most patients with AK, owing to its proven efficacy, good local and systemic tolerability and a short treatment regimen of 5 days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also makes it possible to use flexible therapeutic schedules, including repeated treatment cycles, if needed.
|
| format | Article |
| id | doaj-art-8369101bb515431e9bf0d13b63adaefd |
| institution | Kabale University |
| issn | 2160-9381 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Dermatology Practical & Conceptual |
| spelling | doaj-art-8369101bb515431e9bf0d13b63adaefd2025-08-20T03:42:11ZengMattioli1885Dermatology Practical & Conceptual2160-93812025-07-0115310.5826/dpc.1503a5921Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical InsightsMarco Ardigò0Giuseppe Argenziano1Elena Campione2Stefania Guida3Caterina Longo4Giuseppe Micali5Gianluca Nazzaro6Ketty Peris7Federico Venturi8Alessia Villani9Iris Zalaudek10Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, ItalyDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, ItalyDermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyDermatology Clinic, IRCCS San Raffaele Hospital, Milan, ItalySkin Cancer Center, Azienda Unità Sanitaria Locale, IRCCS Reggio Emilia, Reggio Emilia, Italy; Dermatology Department, University of Modena and Reggio Emilia, ItalyDermatology Clinic, University of Catania, Catania, ItalyDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Physiopathology and Transplantation, University of Milan, ItalyDermatology, Department of Medical Science and Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Dermatology, Catholic University of the Sacred Heart, Rome, ItalyOncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, ItalyDermatology Section, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, ItalyDepartment of Dermatology and Venereology, University of Trieste, Trieste, Italy Introduction: Tirbanibulin, a topical treatment for actinic keratosis (AK) with a novel antiproliferative mechanism of action, has demonstrated efficacy and a favorable tolerability profile in clinical trials and real-life studies. An insight into best-practice use of tirbanibulin in different clinical presentations of AK would be useful. Objectives: The aim of this article is to deliver advice, via expert consensus, on optimal use of tirbanibulin in the real-life management of AK. Methods: A panel of 11 dermatologists with expertise in the treatment of AK convened to develop consensus statements about key aspects of tirbanibulin treatment in AK patients, based on selected literature data and their own clinical experience. Results: Two areas were examined and discussed: clinical assessment/diagnostic procedures and key aspects of tirbanibulin therapy. A total of 19 statements were elaborated and voted, concerning clinical evaluation of AK patients, routine and advanced diagnostic instruments, patient selection, treatment modalities and key messages for patient communication. Conclusion: Tirbanibulin should be considered as a first-line option for most patients with AK, owing to its proven efficacy, good local and systemic tolerability and a short treatment regimen of 5 days. All these factors encourage patient acceptability and treatment compliance. The favorable safety profile and tolerability of tirbanibulin also makes it possible to use flexible therapeutic schedules, including repeated treatment cycles, if needed. https://dpcj.org/index.php/dpc/article/view/5921Actinic Keratosistirbanibulinexpert opiniontopical treatment |
| spellingShingle | Marco Ardigò Giuseppe Argenziano Elena Campione Stefania Guida Caterina Longo Giuseppe Micali Gianluca Nazzaro Ketty Peris Federico Venturi Alessia Villani Iris Zalaudek Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights Dermatology Practical & Conceptual Actinic Keratosis tirbanibulin expert opinion topical treatment |
| title | Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights |
| title_full | Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights |
| title_fullStr | Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights |
| title_full_unstemmed | Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights |
| title_short | Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights |
| title_sort | real world efficacy of tirbanibulin in actinic keratosis treatment expert consensus and clinical insights |
| topic | Actinic Keratosis tirbanibulin expert opinion topical treatment |
| url | https://dpcj.org/index.php/dpc/article/view/5921 |
| work_keys_str_mv | AT marcoardigo realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT giuseppeargenziano realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT elenacampione realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT stefaniaguida realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT caterinalongo realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT giuseppemicali realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT gianlucanazzaro realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT kettyperis realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT federicoventuri realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT alessiavillani realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights AT iriszalaudek realworldefficacyoftirbanibulininactinickeratosistreatmentexpertconsensusandclinicalinsights |